MOREPEN

LABORATORIES LIMITED

Q1'FY23

earnings Presentation - jul 2022

Disclaimer/ Confidentiality

This presentation has been prepared by Morepen Laboratories Limited ("Company") solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.

This presentation has been prepared by the Company based on information an data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise.

The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / advice may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.

This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.

This presentation contain confidential data and information about the company historical performance and future business plan strategy and the any reader/user can not copy, circuculate or use disclose the said information or part of it to anyone without prior written permission of the Company. Any unauthorised use of the data will attract legal action against the person.

.

DEBT FREE COMPANY

The company had long standing liability of

114.65 cr. as outstanding preference capital issued to the Banks/FI's in the 2003/2004

During the quarter the company has converted the outstanding preference capital in to 2.13 cr. Equity Shares of the Company

This was the last leg of CDR and the company now has no payment obligations to Banks/FI's and is a Debt Free Company

C O N S O L I D A T E D

QUARTERLY HIGHLIGHTS

Business is consolidating after Covid pandemic disturbance and expected to stabilise over next 2-3 quarters.

Against peak Covid quarterly revenue of Q1'FY22, the revenues for the current quarter, Q1'FY23, is down by 22%

Current quarterly revenue of Rs. 303 Cr., is up 50% from pre- Covid revenues of Q1'FY20 of Rs. 203 Cr.

On a long term basis (ignoring the Covid peaks) business has grown consistently at CAGR of 14% from Q1'FY20-Q1FY23

Muted demand, lower price recovery, higher input costs has impacted the profit margins for last two quarters and the recent Rupee depreciation is adding additional burden on the costs.

High inventory levels maintained for some Covid products are expected to be realised slowly in coming quarters

CONSOLIDATED

q u a r t e r l y p e r f o r m a n c e

26% CAGR

C O N S O L I D A T E D

REVENUE GROWTH

Rs. in crores

2,000

1,500

^30%

1557

14% CAGR

1200

1,000

863

772

500

0

FY'19 FY'20 FY'21 FY'22

A n n u a l p e r f o r m a n c e

400

388.31 388

300

303

u p 5 0 % f r o m

200

259

p r e - c o v i d l e v e l

203

100

0

Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23

Q 1 ' F Y 2 3 p e r f o r m a n c e

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Morepen Laboratories Ltd. published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2022 11:17:11 UTC.